Business
Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach
WARREN, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, Chairman and founding CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq:
About this update from Tevogen Bio Holdings Inc.
[{"type":"text","content":" WARREN, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, Chairman and founding CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, congratulates Lynne Patton on being appointed Deputy Assistant to the President and Director of Minority Outreach. Ms. Patton will join the Office of Public Liaison and will be responsible for ensuring that President Trump continues to build upon his Election Day support from Blacks, Latinos and Women. Ms. Patton has been one of the Trump family’s longest serving and most trusted aides. Previously, Ms. Patton was the Regional Administrator for Federal Region II at the U.S. Department of Housing and Urban Development (HUD) and Senior Advisor to Secretary Ben Carson. At HUD, Ms. Patton worked tirelessly to bring accountability, reform and results to some of the most challenging housing issues facing our country. From championing the rights of underserved communities to exposing corruption and mismanagement within public housing systems, Lynne consistently fought for fairness and opportunity, earning her the bipartisan respect of industry peers and local elected officials alike. Lynne’s deep connection to the issues affecting minority communities combined with her remarkable interpersonal skills, makes her the ideal person to lead this critical outreach effort. “Being appointed Deputy Assistant to the President and Director of Minority Outreach is both an honor and an opportunity to continue my bipartisan efforts on behalf of the White House in supporting important issues impacting all Americans with a focus on underserved communities, both rural and urban,” commented Ms. Patton. Dr. Saadi added, “Business success can be an unattainable concept unless it contributes to societal prosperity. As a pioneering AI biotech, we are committed to supporting the President’s initiative to advance affordable medical innovation.” About Tevogen Bio Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevog...